InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,645.85
(
0.26%
)
US TECH 100
19,740.80
(
-0.53%
)
Dow Jones
40,808.86
(
1.48%
)
Brent Oil
83.32
(
-1.21%
)
Bitcoin
64,404.20
(
-0.71%
)
Post# of 252610
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120054
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Friday, 06/27/2014 3:38:16 PM

Friday, June 27, 2014 3:38:16 PM

Post# of 252610
GILD submits Japan NDA for Sovaldi/ribavirin in GT2 patients:

http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=1943231&highlight

GT2 is a common variant in Japan, comprising about 25% of the HCV population there. The proposed treatment duration is 12 weeks (the same duration as the FDA label for Sovaldi/ribavirin in GT2).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up